Biotree

About Biotree

Shanghai BioTree Biotech Co., Ltd., officially known as Shanghai AQu Biomedical Technology Co., Ltd., was established in March 2012 within the Fudan Science and Technology Entrepreneurship Park in Shanghai. The company operates as a high-tech enterprise focused on applying mass-spectrometry technology to the life science and medical health sectors. Biotree provides a comprehensive suite of services, including sample testing, big data analysis, and the development of new technologies and products.

The firm's core business revolves around multi-omics research, with a specialization in metabolomics and proteomics. Its service offerings are extensive, covering non-targeted metabolomics, high-throughput targeted metabolomics, lipidomics, and metabolic pathway analysis. The company serves a diverse client base that includes universities, research institutes, hospitals, and pharmaceutical and food enterprises. By 2022, Biotree had established stable cooperative relationships with over 1,500 entities. Revenue is generated by providing these specialized research services and by transforming research findings into commercial products, such as in-vitro diagnostic (IVD) test kits.

Biotree has developed a significant intellectual property portfolio, holding 96 patents and software copyrights collectively with its subsidiaries. A key asset is its proprietary library of secondary spectra for over 200,000 compounds. The company has also brought more than 20 high-throughput mass spectrometry test kits to market and obtained numerous medical device filings and registration certificates. In July 2022, the company secured nearly 100 million yuan (approximately $14.79 million) in a Series A financing round, with the funds designated for expanding its metabolomics research service platform and accelerating the clinical transformation of its products.